ERBB2 and breast carcinoma: Results of the PANACEA clinical trial pertaining to patients with metastatic HER2-positive breast cancer, showed a 15.2% objective response rate to pembrolizumab-trastuzumab combination therapy in PD-L1-positive patients as against 0% in PD-L1-negative patients23.